Key facts
- This page summarizes Michael Harsh's Form 4 filing for ENDRA Life Sciences Inc. (NDRA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jan 2022, 16:05.
Michael Harsh - 03 Jan 2022 Form 4 Insider Report for ENDRA Life Sciences Inc. (NDRA)
- Form type
- 4
- Accepted by SEC
- 04 Jan 2022, 16:05:15 UTC
- Next filing
- 30 Mar 2022
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Michael Harsh by Mark Busch, attorney-in-fact
Source evidence
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Harsh filed Form 4 for ENDRA Life Sciences Inc. (NDRA) on 04 Jan 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NDRA
transaction
Derivative
Stock Options
Award
- Transaction value
- $0
- Shares
- +12,000
- Change %
- Price
- $0.000000
- Shares after
- 12,000
- Date
- 03 Jan 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- $0.7400
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents a stock option award granted on January 3, 2022 pursuant to the Issuer's Non-Employee Director Compensation Policy.